cyrilzakka/clinical-trials huggingface dataset:
Smooth Extubation With Ketofol for Induction of General Anesthesia in Laparoscopic Drilling of Polycystic Ovary

the effect of ketofol, a combination of propofol and ketamine, on hemodynamics and airway response during induction of general anesthesia has been studied before. Its effect on the smoothness of extubation has not been studied before. In the present study; we aimed to assess the effect of ketofol on the smoothness of extubation as regards, airway response, sedation score during suction and extubation and hemodynamic changes comparing it with propofol for induction of general anesthesia.

After securing intravenous access by a 20g catheter, intravenous premedication (midazolam 2 mg and 4mg ondansetron) was administered to all patients. Standard ASA(american society of anesthesiologists) monitoring (5-lead ECG, noninvasive blood pressure (NIBP), and pulse oximetry) was applied to all the patients for the recording of heart rate (HR), NIBP and oxygen saturation by a multiparameter monitor. Induction of general anesthesia was achieved as follows: in Group K (Ketofol group), fifty three female patients received propofol (1mg/kg) plus ketamine (0.5mg/kg) at the induction of general anesthesia while in Group P (Propofol group), fifty three female patients received propofol (2mg/kg) only at the induction of general anesthesia.

Patients in both groups received fentanyl 2 ug\\kg and atracurium 0.5 mg\\kg. After tracheal intubation, general anesthesia maintained by isoflurane 1.5 volume % in 2 L\\min oxygen-air mixture 50:50 and atracurium 0.1 mg\\kg every 30 minutes, if needed. At the end of the surgery, inhalational anesthesia was stopped and reversal of the patients was done by injection of neostigmine 0.05mg\\ kg and atropine 0.01mg\\kg.

Hemodynamics (HR and mean arterial pressure ''MAP'') was assessed at 5 minutes interval from the time of reversal of muscle relaxant up to 30 minutes after extubation.

The level of sedation during suction and extubation was assessed using observer assessment sedation score and the airway response under direct laryngoscopy to suction was noted by five-point scale. After 5 minute interval, the level of sedation and smoothness of extubation was noted by four-point scale.

Eligibility Criteria:
Inclusion Criteria:

* American Society of Anesthesiologists Physical status ''ASA PS'' class I and II scheduled for laparoscopic drilling for polycystic ovary under general anesthesia.

Exclusion Criteria:

* from cardiac, hepatic, renal diseases, history of epilepsy
* Patient refusal.
* known drug allergy.
Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma

The purpose of this study is to evaluate the feasibility and toxicity of the combination of paclitaxel, carboplatin, and topotecan in patients with previously untreated, stage III or IV epithelial ovarian carcinoma or primary peritoneal carcinoma. We will also make a preliminary evaluation of the efficacy of this three drug regimen in the initial treatment of these patients.

Upon determination of eligibility, all patients will be receive:

Paclitaxel + Carboplatin + Topotecan

a maximum of six courses of chemotherapy will be given at 21 day intervals

Eligibility Criteria:
Inclusion Criteria:

To be included in this study, you must meet the following criteria:

* Epithelial ovarian carcinoma or primary peritoneal carcinoma
* Willing to consider second-look surgery to evaluate response if necessary
* No previous treatment with chemotherapy or radiation therapy
* Ability to perform activities of daily living with minimal assistance
* Adequate bone marrow, liver and kidney function
* Written informed consent

Exclusion Criteria:

You cannot participate in this study if any of the following apply to you:

* Age \< 18 years
* Brain metastases
* Recent history of significant heart disease within 6 months
* Other significant medical conditions

Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.
Frozen Shoulder Treated by Energy Accumulator

Frozen shoulder is a painful and disabling disorder of unclear cause, affecting middle-age people after their 5th decades. They suffer from annoying pain and limited shoulder mobility. Energy Accumulator provides a better way of relief through an integrative medicine concept.

Frozen shoulder is common among middle-aged persons in the 5th and 6th decades. The pain can be acute or chronic. Patients feel stiffness over the shoulder, shown by restriction in range of motion. The etiology includes trauma, cervical disc degeneration, physical strain, psychosocial problems and even genetic factors. The predisposing factors include immobilization of the arm for a long time, rotator cuff or biceps tendinitis, tenosynovitis of the long head of the biceps, congenital deformity of the shoulder girdle, scapula-costal cementing, ligamentous injury, osteoarthritis, muscular fibrosis or nutritional deficiencies. The pathology is unclear but it is widely believed that it is related to inflammation in the joint and surrounding soft tissues which lead to fibrosis. Frozen Shoulder can be divided into Primary Frozen Shoulder which occurs spontaneously without other diseases; and Secondary Frozen Shoulder is associated with joint diseases, such as osteoarthritis or fractures.

UKFROST was a multi-centre randomized clinical trial comparing 3 parallel groups (arms) of frozen shoulder patients treated 1) under anaesthesia + steroid injection 2) under anaesthesia + arthoscopy, and 3) physiotherapy + steriod injection..The large-scale study proves physiotherapy program beneficial to frozen shoulder patients, and, the effectiveness might further improve by introducing East-Meets-West component - Chinese Medicine.

Eligibility Criteria:
Inclusion Criteria:

* male or female gender with age between 40-65
* affect one shoulder only
* onset is more than 3 months at the time of inclusion into the study

Exclusion Criteria:

* unstable medical conditions
* unstable mental state
* have skin lesion over the shoulder
* skin sensitivity to heat
* pregnant or under lactation
* could not comply with heat treatment of the shoulder.
Genetic Variants Modulate Association Between Dietary n-3 LCPUFAs and DHA Proportion in Breast Milk

DHA is important for the development of brain and retina in newborns. Considering that exclusive breast feeding for at least 4 \~6 months are globally recommended, plus it is well known that nutrient requirement is determined by both genetic and environmental (including diet) factors, this clinical study sought to investigate how the DHA levels in maternal milk is modulated by genetic variants and dietary n-3 LCPUFA intake. To recruit subjects (n=193), the inclusion criteria are Han Chinese women just having delivered full-term baby, 20-40 years old, healthy, and willing to breast feed their baby for at least 2 months. Written informed consent will be obtained from participants. Personal information (or covariates) such as height, weight (before getting pregnancy and delivery, respectively), age, parity, education, smoking, alcohol drinking, gender of baby...etc, and DNA from oral swab will be collected. Breast milk and dietary data will be collected at the end of the 1st and 2nd month of postpartum period. Considering Han Chinese women usually have special postpartum diets and care during puerperium, therefore, collection of breast milk and dietary information will be repeated at the 2nd month. The fatty acid composition in milk will be analyzed by gas chromatography. Using food frequency questionnaire, intake of n-3 LCPUFA from foods + fish oil supplements will be calculated. Subjects will be instructed to give a 3-days food record as well. We foresee results of this study might contribute to public health care as nutritionists/dietitians will be able to target the vulnerable subjects, who are dietary dependent for DHA, for dedications in nutrition consults or customized dietary guidance. Moreover, these information are valuable in making policy regarding dietary recommendation in Taiwan.


Eligibility Criteria:
Inclusion Criteria:

* Han Chinese women
* Full-term pregnancy(\>36weeks)
* 20-40 years old
* Healthy
* Breast feed their baby for at least 2 months

Exclusion Criteria:

* Death before and after childbirth
* Child with congenital disease
The Effects of Soft Tissue Therapy and Exercise on Hamstring Tightness

The purpose of this study is to investigate the effects of myofascial decompression (cupping) and neurodynamic sliding technique for the hamstring on Division I Track and Field athletes who complain of hamstring tightness. Research questions will be: how do these techniques affect hamstring range of motion and flexibility; isometric strength of the hamstring muscle; muscle activation; and rate of force development. The hypotheses of this study are that neurodynamic sliding will have an effect on all variables and myofascial decompression will only have an effect on range of motion.

Predisposing factors to hamstring injury include neural tension and muscle flexibility restrictions due to fascial adhesions. The sciatic nerve can produce symptoms of pain, decreased range of motion, and increased resting muscle tone when it is overstretched. The nerve can be overstretched after a hamstring injury and cause adhesions on the nerve and abnormal mechanosensitivity leading to perceived hamstring tightness.The purpose of this study is to investigate the effects of myofascial decompression (cupping) and neurodynamic sliding technique for the hamstring on Division I Track and Field athletes who complain of hamstring tightness. Research questions will be: how do these techniques affect hamstring range of motion and flexibility; isometric strength of the hamstring muscle; muscle activation; and rate of force development. The hypotheses of this study are that neurodynamic sliding will have an effect on all variables and myofascial decompression will only have an effect on range of motion.

Eligibility Criteria:
Inclusion Criteria:

* Must be in the Sprints, Jumps, or Multi (heptathlon, pentathlon, or decathlon) groups
* complain of hamstring tightness and/or injury in the last calendar year
* have less than 80⁰ for Active Knee Extension test.

Exclusion Criteria:

* Past history or current neurological disorders or orthopedic diseases
* Surgery of the lower extremity that involves an autograft on the tested leg
* Past history of hamstring surgery
* Receiving current treatment for a hamstring injury
* Received any form of myofascial therapy or neurodynamic techniques within the last week unhealed wounds
* active TB
* leukemia
* hemophilia
* thrombocytopenia
* fever
* influenza
* moderate/severe anemia
* high blood pressure
* cardiac conditions
* late stages of pregnancy
Clinical and Virological Efficacy of Pegylated Interferon Alpha in the Treatment of Rhinovirus Infection in Patients With Primary Hypogammaglobulinemia: Randomized Controlled Trial

The study will investigate the efficacy and safety of subcutaneous interferon alpha -2a to eradicate rhinovirus in patients with primary hypogammaglobulinemia. Patients with hypogammaglobulinemia have persistent rhinovirus infections. Rhinovirus may worsen pulmonary complications. Pegylated interferon alpha with ribavirin appear to effectively clear persistent rhinovirus infections in hypogammaglobulinemia patients.

Patients with primary hypogammaglobulinemia and confirmed respiratory rhinovirus infection will be randomly assigned in a double-blind fashion to receive either

* Group 1: subcutaneous pIFNα2a
* Group 2: subcutaneous placebo Subjects will have scheduled study visits at 1-week and at 2-month after entry to study. In addition, possible bacterial infections will be treated with antibiotics. Each patient will be followed with weekly nasal surveillance samples for 2 months and a symptom diary. Blood draws take place at study entry, 1-week and 2-month time-points.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients (\>18 years),
* primary hypogammaglobulinemia with regular immunoglobulin replacement therapy,
* rhinovirus positive from nasal swab,
* thrombocytes over 90 x109/L,
* Neutrophiles \> 1,5 x109/L
* written informed consent.

Exclusion Criteria:

* Participation to another study,
* need for intensive care unit treatment,
* difficulties to understand national language, pregnancy and breastfeeding,
* any somatic, psychiatric or social disease or issue which in the opinion of the investigator makes participation in the trial not being in the best interest of the subject.
Effectiveness of Fractionated Laser Resurfacing to Protect Geriatric Skin From Actinic Neoplasia

This study is following up on previous studies that have demonstrated that geriatric subjects respond different to ultraviolet B (UVB) light than young subjects. The treatment of geriatric skin with dermal rejuvenation therapies (dermabrasion, fractionated laser resurfacing) restores the appropriate UVB response. Ongoing studies have tested the ability of fractionated laser resurfacing (FLR) to assess how long this wounding effect lasts-and have found that this appears to be a durable response which lasts for at least two years. The findings that FLR protects geriatric skin at two years is the impetus for this study.

This study is an interventional study to assess if FLR treatment of one forearm of geriatric subjects with multiple actinic keratosis will result in the short-term removal of actinic keratosis, and the long-term decrease in levels of future actinic keratosis and other non-melanoma skin cancers in comparison to the untreated arm.

Study length and visit: The first part of the study is completed in 1 day then there are follow up visits at 90 days and every 6 months for 5 years.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with Actinic Keratosis within the past 6 months
* At least 60 years of age, or older
* Ability to comprehend procedures and risks versus benefits
* Able to provide Informed Consent
* Fair Skin (Fitzpatrick Type I or II)
* Possess both Right and Left Forearms

Exclusion Criteria:

* Uncontrolled Diabetes Mellitus
* Not able to comprehend procedures or risks versus benefits
* Pregnant or nursing
* Large tattoos on forearms
* History of abnormal healing or scarring (i.e., keloids)
* Any disease that gets worse while in the sun
* Use of topical or oral anti-inflammatory medication or steroids
* Allergy to lidocaine
* Current use of photosensitizing medication
A Consensus on Opioid Prescription for Oncologic Patients in Latin America - A DELPHI Study.

As seen worldwide, cancer incidence is increasing in Latin America achieving an amount of 1.3 million new cases annually.1 In addition, it is expected that up to 70% of patients with cancer will experience pain2, one of the most distressing symptoms in patients with advanced cancer.

And despite of advances in cancer therapies, opioids remain the mainstay treatment of cancer-related moderate-to-severe and end-of-life pain.3 However, concerns regarding opioid prescriptions have emerged for reasons like the risk of misuse and the possibility of cancer progression.

In the last decades, an increase in consumption of opioids as well as in opioids-related deaths generating the so called 'opioid crisis'. This rise is mainly due to abuse / addiction of opioids. Consequently, oncologic patients are at risk for abuse, as well as for aberrant use, which can complicate the course of cancer treatment.4 5 Another feature of opioids use in cancer patients is that it may contribute to disease progression. Experimental studies suggest that opioids can may lead to immunosuppression and tumor progression or recurrence.6-8 On the other hand, retrospective analysis of clinical data shows conflicting results and trials are lacking.


Eligibility Criteria:
Inclusion Criteria:

* Head of anesthesia, Pain management and palliative care departments of cancer hospitals in Latin America.

Exclusion Criteria:

* Surveys not answered.
Gene Expression Profiling in a Validation Cohort of Locally Advanced and Recurrent/Metastatic Salivary Gland Cancers

The INDAGA-UK trial is a retrospective, multi-centre observational study in participants with locally advanced and recurrent salivary gland to investigate t its molecular profiling, and to explore new prognostic and druggable markers. We will analyse samples and data from patients diagnosed with salivary gland cancer from 2013 - 2023. Subject and sample identification will occur over a 12-month period. Samples and data will be analysed over the next 12 months prior to study end.


Eligibility Criteria:
Inclusion Criteria:

1. Aged over 18
2. Histological diagnosis of salivary gland cancer (SGCs)
3. Availability of archival tissue (acceptable after 2013 up to present)
4. Ability to give informed consent (if applicable)\* for retrieving histological specimen and preform molecular analysis \*De-identified archival tissue from deceased patients will be collected as part of the study once REC approval is in place, if the patient was alive when the samples were taken and they are not part of the NHS opt out scheme.

Exclusion Criteria:

1. Different H\&N cancer of other histology
2. Thyroid cancers
Ethanol Lock and Risk of Catheter Related Blood Stream Infection in Patients With Haemodialysis Catheter

The aim of this study is to examine the effect of ethanol (70%) as lock-solution after hemodialysis on:

* The frequency of dialysis catheter-related bacteremia among patients under observation of potential complications
* Other complications of the use of hemodialysis-catheters eg. dysfunction of the catheter due to thrombosis.


Eligibility Criteria:
Inclusion Criteria:

* Age at or above 18 years.
* Currently recieving hemodialysis treatment with tunneled intravenous hemodialysis-catheter
* Written informed consent after verbal and written information is given.

Exclusion Criteria:

* Pregnancy or breastfeeding
* Intolerance to ethanol or contraindications for the use of ethanol. Eg. possible interactions, former alcohol dependency.
* Earlier infections to current catheter (exit-site, tunnel-infection and catheter-related bloodstream infection
The Natriuretic Peptide Response to Saline Infusion

The primary objective is to evaluate the overarching hypothesis that obese and black individuals have relatively lower circulating natriuretic peptide levels compared with lean and white individuals. Conventional clinical assays for measurement of circulating natriuretic peptides display substantial overlap, precluding determination of the basis of the relative natriuretic peptide deficiency previously observed in these groups. We will study lean or obese, black or white, healthy adult subjects with intravenous (IV) saline infusion as a stimulus for natriuretic peptide production and release. We will measure circulating levels of natriuretic peptide isoforms using mass spectrometry that allows the specific identification of proBNP 1-108 and its cleavage product BNP 1-32.


Eligibility Criteria:
Inclusion Criteria:

* Age between 18 and 65 years;
* BMI between 18 and 25 (lean) or 30 and 40 kg/m2 (obese);
* self-reported race of either black or white;
* otherwise healthy with no chronic comorbidities.

Exclusion Criteria:

* History of diabetes mellitus
* Currently pregnant
* History of cardiac disorder including heart failure, cardiomyopathy, myocardial infarction, coronary revascularization, abnormal stress test, uncontrolled arrhythmia or arrhythmia requiring treatment, congenital heart disease, pericardial disease.
* History of hypertension defined as taking anti-hypertensive medications or untreated hypertension with systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg at most recent clinical visit or screening visit.
* Obstructive lung disease
* History of chronic kidney disease
* History of liver disease or cirrhosis
* Uncontrolled thyroid dysfunction
* History of solid organ transplant
* History of malignancy other than basal or squamous cell skin cancer
* Inability to lie flat for 6 hours
OUD (Opioid Use Disorder) Target Trial

In this research study the investigators will work with 80-participants with opioid use disorder who are starting treatment with the medication buprenorphine and are trying to quit using opioids.

The investigators are trying to learn two things:

1. Can an MRI brain marker be used to predict which participants will be successful in quitting opioids with buprenorphine?
2. Does adjunctive treatment with repetitive Transcranial Magnetic Stimulation (rTMS) help people quit using opioids more than a sham (placebo) version of rTMS?

In order to complete the study the investigators will ask participants to:

* Complete an MRI within 5-days of starting buprenorphine and again after they are on a full stable dose 1-3 weeks later.
* Undergo study-treatment with 50-sessions of either real or placebo rTMS in as little as 1-week (10-sessions-per-day for five days) or as long as over 6-weeks.
* Meet with the investigators once per week over the following 12-weeks to see if the participants have been able to quit using opioids over that time.


Eligibility Criteria:
Inclusion Criteria:

1. Age 18 or older; all genders included.
2. Intellectual level sufficient to provide informed consent and accurately complete assessment instruments (English speaking/writing).
3. Meet DSM-5 criteria for moderate or severe OUD. Individuals may also meet criteria for another substance use disorder (with the exception of alcohol or sedative/hypnotic); but must identify opioids as their primary substance.
4. Starting buprenorphine and planning on opioid abstinence

Exclusion Criteria:

1. Pregnant, breast-feeding, or planning on getting pregnant.
2. Alcohol or sedative/hypnotic use disorders (seizure risk).
3. History of/or current psychotic disorder (e.g. schizophrenia).
4. Current or lifetime bipolar disorder.
5. Unstable Axis-I condition requiring starting a new medication.
6. Active suicidal ideation / suicide attempt within 90 days.
7. History of/or current dementia or other cognitive impairment.
8. Contraindications to receiving rTMS or undergoing MRI (implanted ferromagnetic metal, history of or high risk of seizure, implanted device).
9. Unstable general medical conditions.
Family Based Intervention in Childhood obesitY

The study compares the effect on BMI of two different treatment options for obesity in childhood. Families with at least one obese child and parent are invited to join the project. The hypothesis is that family camp gives an additional reduction in BMI compared to a less intensive family lifestyle school.

Participants are randomised to two intervention groups:

A): Two weeks family camp and two years follow-up as a cooperation with primary health care, private rehabilitation center and specialist health care.

B): Four days lifestyle school with two years follow-up as a cooperation with primary health care and specialist health care

Eligibility Criteria:
Inclusion Criteria:

* age 7 to 12 years
* BMI \> iso-BMI 30 (Coles index)

Exclusion Criteria:

* syndromatic obesity
* obesity related to diseases
* local community not involved
* child has present follow-up because of obesity in secondary health care
* parent has present/planned follow-up because of obesity in secondary health care